HLA-B*1502 screening and toxic effects of carbamazepine [1]

New England Journal of Medicine

Volumn 365, Issue 7, 2011, Pages 672-673

  Phillips, Elizabeth J ^a   Mallal, Simon A ^a  

^a Institute for Immunology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; HLA B1502 ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG USE; GENE FREQUENCY; GENE LOCUS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; LETTER; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 80051841201     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1105467     Document Type: Letter

References (5)

1. Chen P., Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126-1133
2. Man C.B., Kwan P., Baum L., et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-1018[Erratum, Epilepsia 2008;49:941.] (Pubitemid 46763406)
3. Hung S.I., Chung W.H., Liu Z.S., et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-356
4. Locharernkul C., Loplumlert J., Limotai C., et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-2091[Erratum, Epilepsia 2009;50:971.]
5. FDA alert: phenytoin and fosphenytoin information. Silver Spring, MD: Food and Drug Administration, November 24, 2008. (http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110259.htm. )